FOXP3 and neoplasm: Second, the relative abundance of CD4+Foxp3+ Tregs at the tumor site was substantiallylower in mice that received the NIE-NPs treatment than that in micetreated with CNIE-NPs, i.e., 4.97% vs 13.0%.